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Abstract 
Observational studies are a basis for much of our knowledge of veterinary pathology, yet 
considerations for conducting pathology-based observational studies are not readily available. 
In part 1 of this series, we offered advice on planning and carrying out an observational study. 
Part 2 of the series focuses on methodology. General recommendations are to consider using 
already-validated methods, published guidelines, data from a primary source, and quantitative 
analysis. We discuss 3 common methods in pathology research—histopathologic scoring, 
immunohistochemistry, and polymerase chain reaction—to illustrate principles of method 
validation. Some aspects of quality control include use of clear objective grading criteria, 
validation of key reagents, assessing sample quality, determining specificity and sensitivity, 
use of technical and biologic negative and positive controls, blinding of investigators, 
approaches to minimizing operator-dependent variation, measuring technical variation, and 
consistency in analysis of the different study groups. We close by discussing approaches to 
increasing the rigor of observational studies by corroborating results with complementary 
methods, comparing results among many different animals, consideration of similar published 
studies, replicating the results in a second study population, and critical analysis of the study 
findings.  
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Observational studies are the most frequent study type published in the pages of Veterinary 
Pathology and fundamentally guide the daily practice of veterinary pathologists. Although 
advice is available from other disciplines, it may be difficult for veterinary pathologists to apply 
these guidelines to the types of observational studies they typically conduct. The first article of 
this series focused on design and development of observational studies.6 In the current article, 
we—editors and editorial board members of Veterinary Pathology and their colleagues—focus 
on principles of method validation and quality control. These are discussed in the context of 3 
methods commonly used by veterinary pathologists: histopathologic scoring, 
immunohistochemistry, and polymerase chain reaction (PCR). We emphasize that this article 
is neither intended as a ‘cookbook’ for validating these methods nor as a list of requirements 
for publishing in Veterinary Pathology. Instead, we focus on using these examples to illustrate 
considerations and principles that are relevant to any investigative method (Table 1). 
Innovative methods can provide unexpected answers to longstanding and important questions. 
However, the methods should not be the basis for the study, but instead are used to address a 
hypothesis, question or objective backed up by a clear rationale. If the study objective is this 
journey’s roadmap, then the methodology is the vehicle’s engine. Studies with a clear objective 
can cruise toward their destination while still having resources to spare for stops at points of 
interest along the way. Alternatively, investigations built only on the novelty of a method tend to 
pleasantly ramble through an interesting landscape but never find a destination.  
Investigators are also directed to the reporting guidelines available for many analytic methods, 
which are also relevant to study design and method validation (Minimum Information for 
Biological and Biomedical Investigations; https://fairsharing.org/collection/MIBBI). Of particular 
relevance are those for veterinary observational studies (STROBE-Vet36,44), animal studies 
(ARRIVE: https://www.nc3rs.org.uk/arrive-guidelines), diagnostic test accuracy (STARD9,15), 
immunohistochemistry and in situ hybridization (http://mged.sourceforge.net/misfishie/), flow 
cytometry (http://flowcyt.sourceforge.net/miflowcyt/), and reverse transcription-quantitative 
PCR (RT-qPCR; http://www.rdml.org/miqe.php). 
Microscopic assessment 
Diagnosis, classification, and scoring or grading of microscopic lesions are mainstays of 
pathology research. Because these methods are subjective and sometimes challenging to 
quantify, effective study design and validation of methods are particularly critical. Errors in 
measuring lesions result in imprecision and variability of the data, thereby reducing the 
likelihood of detecting a difference between study groups. Furthermore, systematic errors that 
differ between the study groups may cause differential information bias that could lead to a 
spurious outcome of the study. Guidelines for histologic scoring and grading have been 
published16,23,30,32,45 including a series in Veterinary Pathology on scoring histologic lesions in 
comparative pathology research,22,24,25,31,51 and guidelines and insights on cancer grading 
studies are available.29,54  
Validate information obtained from others 
At the beginning of a new study, at least one of the investigators with appropriate training and 
experience should validate all of the original pathologic diagnoses by re-evaluating the 
histologic sections or descriptions of the gross postmortem findings using a single set of 
criteria. Do not rely only on the original diagnosis in the pathology report, because differences 
in diagnostic criteria and individual tendencies are likely to introduce variation and perhaps 
error into the study. 
Obtain data from the primary source, if the pathology records are likely to contain errors. We 
all recognize the frequency of omissions and mistakes in the clinical histories submitted to 
pathology laboratories. Thus, as an example, the clinical diagnoses and clinical findings should 
be obtained directly from the clinical case records and not based only on the pathology record. 
Even then, it should be recognized that variation among clinicians or inconsistency in recording 
clinical findings may affect the quality of the data. 
Definition of the outcome 
Clear, objective and reproducible criteria are essential for defining the outcome. For example, 
studies of equine sarcoma and canine liposarcoma provide examples of clearly defined 
characteristics for each neoplasm.1,12 Another study included a schematic, microscopic 
images, and detailed description of cytologic grading criteria (Figure 1).27 Visual guides such 
as these are highly useful to clearly define the cut points between grades and thus reduce both 
intra- and inter-observer variation.   
Diagnostic criteria are more clear and reproducible if they are based on objectively observed 
lesions instead of the inferred morphologic diagnosis. This is particularly important when the 
diagnostic terms have subtly different meanings among pathologists. For example, “interstitial 
pneumonia” is used differently among pathologists, whereas the descriptive term “the 
presence of lymphocytes within pulmonary alveolar septa” should be uniformly understood.  
A clear, objective, and precise definition of the outcome is expected to reduce variability of the 
data, improve understanding of the study methods and results, and make it easier for readers 
to apply the study findings to their own caseload.29 Some of our current cancer grading 
schemes lack clarity or require subjective assessments or interpretations. “Severity of nuclear 
pleomorphism” and “degree of differentiation” are examples of criteria that cannot be 
consistently applied to tumor grading by different individuals. Even “percentage of necrosis” is 
of dubious consistency because the amount of necrosis depends on which parts of the tumor 
were examined.29 For studies of new grading schemes, investigators should measure the inter-
observer variability, ideally using experienced collaborating pathologists who are provided with 
no additional training other than the grading criteria used in the study. This tests whether the 
criteria are sufficiently clear, and reflects the likelihood that a grading scheme can be reliably 
applied to daily practice.46 If collaborators cannot use the published methods to replicate the 
results, then it is unlikely that others will be able to validly apply the grading scheme to their 
clinical case material.29,46  
Defining the scope of analysis 
The breadth of the histologic analysis should be considered. One approach maximizes the 
breadth of assessment in order to more comprehensively analyze each study subject. Multiple 
samples of the lesion are studied, multiple assessments or measurements are made on each 
sample, and multiple non-target tissues are examined. This approach is expected to improve 
the understanding of each individual case and may reduce technical or within-animal variance. 
The converse approach is to conduct a more limited assessment of each animal, so that more 
individuals can be included in the study. This approach is expected to more accurately reflect 
biologic or between-animal variance and may thereby increase statistical power: if systematic 
biases are avoided, then minor inaccuracies may be compensated by an increased number of 
subjects. The balance between these two approaches depends on the number of available 
cases and the study objectives. If there are few cases then intensive analysis of each of them 
will improve the data, whereas if numerous cases are available then a more focused analysis 
of all of them will improve the statistical power. A broad-based investigation might be 
appropriate in an exploratory or descriptive study. However, a focused analysis allows for a 
more directed interrogation of a specific question.  This can allow the investigators to 
triangulate on testing a specific hypothesis, spend more time and energy on validating the 
results, and streamline the story that will become the manuscript. Intensive investigation of a 
single case or very few cases might reveal something new, but analysis of a large number of 
cases is generally needed to ensure the findings are consistent and applicable to the larger 
animal population.  
Validation of the methods 
Repeated analysis of all or a subset of the same samples (separated by a “wash-out” period to 
reduce recall) is an important validation of the histopathology data and measures the technical 
variability or the consistency of scores assigned by a single individual.16 
If assessment of inter-observer variation is an objective, each parameter should be 
independently evaluated by 3 or more of the authors. The variability among observers is 
quantified by kappa analysis for binary data, or by other approaches for continuous data. For 
example, canine mast cell tumors were independently graded by 3 anatomic pathologists and 
3 clinical pathologists, with 72-77% agreement for the various grading schemes.4 In contrast to 
some diagnostic tests, there may not be another “gold standard” for validating histopathologic 
data, but measuring the consistency of diagnoses among different pathologists can serve a 
similar purpose. 
Avoiding technical error, bias and confounding 
Pathology data can have poor intra-observer and inter-observer consistency. As discussed 
above, variability is minimized if grading criteria are precisely defined, based on observed 
lesions instead of inferred diagnoses, and illustrated by examples or a visual grading key. 
Ensure that the individual who makes the assessments or carries out the methods has 
sufficient training, experience and knowledge, as the results are expected to be more uniform 
and more accurate than those assigned by non-experts.42 Conversely, inadequate training and 
experience with the grading method may reduce the ability to detect a difference between 
groups. 
The different study groups must be analyzed in the same way. All samples should ideally be 
analyzed by the same individual. Alternatively, diagnoses or scores can be assigned by 
consensus among a team that evaluates each sample in a standardized way. If it is necessary 
that different cases are evaluated by different individuals, be sure the assignments are 
randomized, and incorporate a statistical comparison of the different individuals into the study 
design. Histologic sections from the study groups should be examined concurrently in random 
order, instead of sequentially analyzing the different study groups. Evaluation of all subjects 
should be done within a narrow time period to avoid “diagnostic drift”.45 
It is imperative to ensure blinding (masking) of the person making the histologic diagnosis, or 
assigning a histologic score, or making other subjective assessments of outcomes. These 
outcomes should be measured without knowledge of the study group or other data; that is, 
without prior knowledge of either the exposure or the outcome. Most observational studies 
employ a 2-step process. First, tissues are examined in a non-blinded manner to identify the 
important criteria to be measured and to establish cut-points between the different histologic 
grades, and then those few specific lesions that are most relevant to the study objectives are 
scored in a blinded formal analysis. Finally, recognize that blinding may be impossible in 
pathology-based studies if the observations defining the exposure and the outcome cannot be 
made independently. For example, immunohistochemistry findings cannot be assessed 
independently of tumor subtype, if the morphology of the tumor is evident on the 
immunolabelled glass slide. In such instances, consider how this might cause a differential 
information bias, and how the impact can be minimized by ensuring the data are collected as 
objectively as possible. 
It is critical to ensure that the study groups are comparable in order to avoid selection bias, 
information bias or confounding. This issue is particularly relevant for studies of archived 
samples or data not acquired for the purpose of the study. Analysis of the pathology records 
may not be sufficient to ensure that the 2 study groups were drawn from similar populations; 
information from clinical hospital records, owner interviews, or knowledge of laboratory 
protocols may be required. Further, consider if there might there be differences between cases 
and controls in the details of how samples were obtained, processed or analyzed. Failure to 
ensure that the study groups are comparable and investigated in a consistent manner may 
result in spurious findings, as discussed in the first article of this series.6  
These factors argue in favor of systematic methodology for routine diagnostic investigations, 
especially for those involving case material that is likely to be used for future observational 
studies. This approach has been particularly useful in investigations of wildlife disease. For 
example, routine mortalities of harbor seals had been investigated in a standardized manner 
including recording of life history data, necropsy methods, and sampling of tissues and sera. 
These provided an effective control group for comparison to harbor seals that died during a 
phocine distemper epidemic, with respect to analysis of antibody titers, morbillivirus infection, 
gross and microscopic lesions, and bacterial isolates from lung and other organs.41 Similarly, 
consistent collection of demographic data (sex, body weight, geographic location, etc) and 
standardized necropsy methods including evaluation of the vascular system and collection of 
muscle samples, were key to analytic studies of muscle pathology and verminous arteritis in 
stranded cetaceans.10,48 
Immunohistochemistry 
Immunohistochemistry is a cardinal method in veterinary pathology, yet it is a technically 
complex procedure. The many variables in the method allow the possibility of technical error 
unless assays are optimized and validated for the species, tissue and application of interest. 
Once validated, quality control procedures are necessary for reliable analysis of samples used 
in the study. The details of immunohistochemistry validation and quality control are described 
elsewhere.17,20,30,38,52,53 
Antibody validation 
The sensitivity and specificity of the primary antibody is fundamental to the 
immunohistochemistry method. Analytic sensitivity reflects the smallest amount of the intended 
target antigen that can be detected. For example, a low-affinity antibody can cause weak 
labelling that is not easily differentiated from background staining, or an antibody may fail to 
react with the expected antigen in a non-target species. Conversely, analytic specificity reflects 
whether the antibody reacts only with the intended target antigen. Cross-reactivity with a non-
target antigen can lead to false-positive labelling that may be difficult to recognize (Figures 2-
3). Note that these terms—analytic sensitivity and specificity—are related to but different from 
diagnostic sensitivity and specificity as used in the context of epidemiology studies (i.e. the 
proportion of truly positive and truly negative animals that are correctly classified by the test, 
respectively).  
Where possible, veterinary pathologists should use antibodies that have been previously 
validated for immunohistochemistry in the species of interest. For example, an antibody raised 
in rabbits against a human protein may not react with the corresponding canine protein, and 
may react with other unrelated canine antigens. It has been estimated that 75% of 
commercially available antibodies are non-specific.55 When it is claimed that antibodies have 
been validated in the dog, consider if the supporting data are available and if they are 
compelling. If not, investigators must be aware that antibody validation is not trivial, yet it is 
essential to the credibility and truthfulness of the results. 
There are several approaches to validating the analytic sensitivity and specificity of an 
antibody.52 One approach is to show immunolabelling in cells or anatomic locations expected 
to express the antigen, and absence of immunolabelling in cells expected to not express it. For 
example, immunolabelling is compared in epithelial vs connective tissues of the skin, or in T- 
vs B-cell areas of lymph node, or in cortex vs medulla of the adrenal gland. However, this is of 
limited value for antigens that do not have cell- or tissue-specific expression patterns. The 
subcellular pattern of immunolabelling may also reveal a problem with antibody specificity, if 
this does not match the expected membranous, cytoplasmic or nuclear location of the protein. 
A second approach is western blot analysis of the tissue or tumor being studied (eg. canine 
lymphoma). An alternative is to use a normal tissue from this species that is known to express 
the target protein (eg. canine lymph node). In the western blot, the antibody should label a 
band of the expected molecular weight for the target protein. If there are additional bands, 
these could be analyzed by mass spectrometry to determine if they are a non-target protein, or 
variants or isoforms of the target protein. These additional bands are highly relevant: while 
target and non-target antigens can be differentiated on western blots based on molecular 
weight of the protein bands, these signals are indistinguishable by immunohistochemistry. An 
important caveat that limits the value of this approach is that the labelling pattern in western 
blot analysis of fresh tissue may differ from that in formalin-fixed tissues. The proteins in a 
western blot are denatured, and the process of formalin fixation and paraffin embedding may 
alter the protein conformation and thus affect the epitope recognized by the antibody. 
Consequently, immunolabelling of the target antigen or of a cross-reacting antigen in the 
western blot does not necessarily mean the same reaction would occur in fixed tissues, and 
vice versa.38  
An example of validation by western blot is provided by a study of canine liposarcoma that 
used an antibody validated for detection of mouse and human MDM2. A western blot of normal 
canine testicular tissue probed with this antibody showed a single band of 90 kDa molecular 
weight as expected for canine MDM2.1 Conversely, when normal and neoplastic canine 
mammary tissues were probed with an antibody approved for HER2 assessment in human 
breast cancer, the western blot did not label any protein at the expected molecular weight of 
canine HER2 (138 kDa). In this analysis, the antibody labelled 2 other bands (50-60 kDa), and 
mass spectrometry showed that these bands did not contain HER2. This cross-reactivity may 
have been responsible for the unexpected cytoplasmic immunolabelling of neoplastic cells and 
labelling of non-neoplastic cells, which were observed when canine tissues were probed with 
this antibody.3,40 These are disruptive findings: they challenge the validity of previously 
published studies, and question the use of canine mammary tumors as a model of HER2 over-
expressing breast cancer.3  
A third approach to validating antibody specificity is to compare cells that are engineered to 
express or not express the target protein. One method is to transfect non-expressing cells with 
the gene of interest (Figure 4). A second method is knockout or knockdown of the gene of 
interest in cells that naturally express it. Expressing and non-expressing cells can be fixed in 
formalin, and immunoreactivity is compared in histologic sections of the different cell pellets. 
Note that this approach may not detect immunoreactivity against cross-reacting antigens, 
because complex tissues include a greater diversity of proteins than are expressed by the 
negative control cell line. 
A fourth approach is competitive inhibition or adsorption. In this procedure, antibody is pre-
incubated with an excess of the purified antigen (or adsorbed using antigen-bound beads) 
before applying it to the tissue section, and the resulting neutralization of the antibody’s binding 
site is expected to abrogate immunolabeling. 2,47 However, this method may not rule out cross-
reactivity with proteins containing an epitope similar to that of the target protein, or if the 
antibody has greater affinity for the target antigen compared to the non-target antigen.17,52  
A fifth approach is in silico comparison of the amino acid sequence of the target protein among 
species. This can be used to infer cross-reactivity, particularly when the epitope targeted by 
the antibody is known, although it does not directly confirm antibody specificity. 
Additional approaches include a comparison of immunolabelling patterns using 2 or more 
antibodies that bind different epitopes of the target protein, a correlation of 
immunohistochemistry findings with those of another analytical method such as in situ 
hybridization, ELISA or RT-qPCR, and immunocapture followed by mass spectrometry.17,52  
Assay validation 
In addition to validating the primary antibody, it is necessary to validate the assay as a whole: 
the combined effectiveness of sample preparation, reagents, buffers, antigen retrieval, 
blocking, antibody avidity and specificity, batch-to-batch variability of antibodies, incubation 
conditions, detection platforms, and the ability of individual observers to interpret the findings. 
This is done by demonstrating positive reactivity in tissue known to express the protein of 
interest, and negative reactivity in tissue known to not express the protein of interest. Here we 
take a qualitative approach to assay validation; quantitative measurement of test accuracy, 
sensitivity and specificity is described elsewhere.9,13,15 
The positive control is used to detect a false negative outcome. For an infectious agent, 
tissues could be obtained from samples known to be infected or not infected, such as from an 
experimental challenge study or based on another method such as RT-qPCR. For tumor 
markers, positive controls are normal tissues known to express the antigen and negative 
controls are those known not express the antigen. Cell lines that naturally express the protein 
or are engineered to do so are alternatives.19 Ensure that immunolabelling is not only present 
in the positive control, but that it has the expected extent and distribution of the antigen within 
the tissue, considering the cell types that are labelled and whether the labelling is nuclear, 
cytoplasmic or membranous.  
Negative controls identify non-specific labelling and thereby identify false-positives. The first 
negative control—the technical negative control—uses the positive control tissue but replaces 
the primary antibody with a non-antigen-specific substitute. If the primary antibody is a 
monoclonal antibody, the negative control should be an irrelevant monoclonal antibody of the 
same concentration and isotype. In the same way, purified immunoglobulin is a technical 
negative control for purified polyclonal antibodies, and pre-immune serum or normal serum 
would be appropriate if immune serum were used as the primary antibody. Omission of the 
primary antibody is often used as a negative control for diagnostic case material once the 
method has been well-validated and is in routine use. However, in our opinion, this is 
insufficient for assay validation or in assays that have some nonspecific background staining. It 
is important to note that the technical negative control does not assess nonspecific labeling 
with the primary antibody; if the antibody cross-reacted with an unrelated antigen, the staining 
would be abrogated by replacement or omission of the primary antibody. Additional technical 
negative controls may be useful in troubleshooting problems when validating a new assay. 
The second negative control—the biologic negative control—should normally include both 
lesional tissue samples as well as normal tissues. Sometimes, a single organ may contain 
different tissues that can serve as positive and negative control (such as epidermis adjacent to 
a tumor). Tissues from 10 positive and 10 negative individuals have been suggested as a 
minimum for analytic validation and can be inexpensively analyzed in tissue microarrays or 
multi-tissue blocks.13 Tissues used for validation must be processed in the same way as would 
be done for clinical specimens, including fixation and decalcification. 
These guidelines apply to qualitative analysis of the presence or absence of immunolabeling, 
and do not measure test sensitivity and specificity in an epidemiologic context. Furthermore, 
additional validation is needed for quantitative immunohistochemical analysis, if the goal is to 
compare the immunolabelling scores with pathogen load, or to compare the findings of two 
different antibodies. 
Quality control 
When using a validated assay to analyze samples from the study, one aspect of quality control 
is to ensure the immunohistochemistry procedures remain effective. These use the same 
approaches as described above and can be considered as external positive and negative 
controls.  
The second aspect of quality control is to provide sample-specific validation of every 
specimen, and can be considered as internal positive and negative controls. False negative 
findings might result from a problem with an individual sample such as prolonged fixation or 
inadequate fixation, excessive decalcification, prolonged exposure to air or light, absence of 
the lesion within the sample, necrosis of the tissue, or errors in sample processing. Such 
problems are ideally identified by use of an internal positive control, such as labelling of normal 
tissue within a tumor sample. Alternatively, positive immunolabelling of a different antigen 
provides some reassurance that the sample is suitable for analysis. However, antigens differ in 
their susceptibility to the above problems, so positive labeling of one antigen does not rule out 
false negative test for the antigen of interest. Knowledge of how the samples were processed 
can also be helpful in this regard. 
Conversely, false positive findings represent non-specific staining and are detected by an 
internal negative control (labelling of an area of tissue not expected to contain the antigen; 
Figure 5), and secondly by applying an isotype-matched irrelevant antibody to a different 
section of the same sample. 
Immunohistochemistry is a wonderful tool for co-localization of lesions and antigens, but 
careful attention to method validation is essential to avoid misleading results. As discussed 
below, confirmation of immunohistochemistry findings by a second analytical method can 
provide additional rigor.  
Polymerase chain reaction 
Assay validation 
While it is true that PCR assays provide more objective data than the subjective interpretations 
sometimes required for histopathology or immunohistochemistry, effort is nonetheless required 
to ensure PCR data are valid. A first step it to ensure that the assay is measuring the intended 
target. For either conventional or quantitative PCR (qPCR), the primer and probe specificity 
should be confirmed by BLAST search against the target and non-target species, and by 
sequencing the amplified products. For quantitative PCR, additional confirmation is provided 
by analysis of the amplification curve, product melting curve and melting peaks for each 
reaction (Figure 6). Use of labeled probes can be valuable to provide additional specificity.  
False-positive outcomes are further avoided by use of negative controls, and these may 
include 3 forms that address different potential problems. First, using water in place of DNA 
template from the sample distinguishes positive from negative results. Second, for reverse 
transcription PCR (RT-PCR), a positive sample processed without reverse transcriptase would 
detect false positive results caused by sample contamination. Third, cross-reactions should be 
further ruled out with samples representing alternative disease conditions and using the same 
sample matrix as clinical samples.49 Examples include testing an assay for Mannheimia 
haemolytica against a panel of other bacteria,18 testing an assay for detection of ovine 
herpesvirus-2 infection in cattle and sheep against other species of animals infected with 
closely related herpesviruses,37 and measuring the sensitivity and specificity of RT-qPCR for 
bovine respiratory syncytial virus compared to an established assay.50 
Quality control 
Following validation of the method, quality control is required in each run of the analysis to 
ensure valid results. Negative controls may include water in place of DNA template, as well as 
a positive sample processed without reverse transcriptase as described above. False-positive 
results due to cross-contamination were prevented in 1 investigation by using a new 
microtome blade for each sample, and forceps cleaned with detergent and alcohol.12  
The positive control—analysis of a known positive sample or a synthesized nucleic acid 
target—would detect a general failure of the assay. However, this would not detect sample-
specific false negative results such as those caused by sample degradation, poor yield or poor 
quality of nucleic acid, inadequate deparaffinization, the presence of PCR inhibitors, or 
polymorphisms or splice variants at primer binding sites. Thus, nucleic acid integrity and purity 
should be measured. Additional sample-specific quality control measures were previously 
illustrated for an assay detecting fungal nucleic acid: a conserved mammalian gene was also 
amplified as a sample-specific positive control to ensure sample quality, and all test-negative 
samples were spiked with positive control DNA to investigate the possibility of PCR inhibitors.28  
For quantitative PCR, additional standard quality control procedures include a dilution series 
(standard curve) of the positive control for each plate of reactions, establishing the crossing 
point at which samples are considered reliably positive, documentation that values for samples 
fall within the dynamic range of the assay, analysis of amplification efficiency for each gene 
targeted, consideration of the method used to normalize data obtained from different runs, 
establishing the repeatability and reproducibility of the assay, and validation of reference 
(“housekeeping”) genes including changes induced by the stimulus being studied. Readers are 
further directed to technical guidelines for analysis of gene expression (miqe.gene-
quantification.info). 
Quantitative assessment and statistical analysis 
In general, for analytic studies, quantitative or semiquantitative assessment of pathologic 
findings is preferred over a descriptive narrative, because it allows statistical analysis of the 
data and formal comparison of study groups. As an example, cluster analysis of multiple 
quantified parameters was used for unbiased analysis of glomerular diseases in dogs, which 
defined and validated their morphologic categorization as membranoproliferative and 
membranous patterns of immune complex–mediated glomerulonephritis, glomerular 
amyloidosis, glomerulosclerosis, and normal.8 When a difference between two groups is 
identified, the level of certainty beyond chance is estimated by the P value. However, the 
statistical analysis should not end with the P value. As important, the magnitude of the 
difference between study groups is summarized by the risk ratio or odds ratio for categorical 
data or the mean difference between groups for continuous data. Finally, the study data are 
only an estimate of the truth: the 95% confidence interval considers the variability of the data 
and the sample size to estimate the range in which the actual (true) parameter likely lies, and 
is therefore essential for valid interpretation of the results. 
It is a rare veterinary pathologist who has deep knowledge of statistical analysis. Given the 
effort put into designing and carrying out an observational study, why risk a deceiving outcome 
caused by inappropriate statistical analysis? Seek professional help in the planning stage to 
ensure an effective study design, and after the study is completed to have confidence in the 
analysis. Common pitfalls in statistical analysis are discussed in an upcoming commentary in 
Veterinary Pathology.31 Readers are also directed to the “Statistics simplified” series published 
in 2011 in the Journal of the American Veterinary Medical Association. 
Approaches to increased rigor 
Rigor involves an approach to conducting research that ensures the findings reflect the truth. 
Casadevall described 5 pillars of scientific rigor: redundancy in experimental design, sound 
statistical analysis, recognition of error, avoidance of logical traps, and intellectual honesty.5 
How can we achieve rigor? First, examine your motivations for conducting the study. Surely, a 
passion for finding the truth motivates most of us in these endeavors. How far are you willing to 
go to bring rigor to your investigations and ensure the study outcomes are valid?  
One way is to replicate the technical analyses on different occasions. Especially for 
unexpected or pivotal findings, key analyses should be repeated on a different day, ideally 
using different samples from the same study subjects. This is done routinely for in vitro 
experimental studies, but may be impossible for observational case-based studies.  
Another way is to use different methods to show the same finding, an approach known as 
triangulation.34 Particularly for unexpected outcomes, choose complementary methods that 
address a different aspect of biology and therefore greatly increase the confidence in the 
findings. Probe the research question from different angles for “validation of tissue 
pathobiology”16 by using combinations of morphologic and molecular pathology, clinical 
biochemistry, clinical observations, diagnostic imaging, epidemiologic analyses, and 
microbiology assays, as examples. For example, a study used immunohistochemistry, 
polymerase chain reaction and in situ hybridization as redundant methods to demonstrate 
canine papillomavirus within pigmented plaques that progressed to squamous cell 
carcinoma.26 Imaging can be used to corroborate the histopathologic findings. For example, X-
ray fluorescence microscopy and Raman spectroscopy were used to characterize metal alloy 
and oxalate crystals within tissues, respectively.11,33 Bone metastases were verified by both 
histopathology and computed tomography.7 Just as you wouldn’t invest retirement savings in a 
single stock, we shouldn’t base our understanding of a disease on a single methodology.  
Critically consider how the study findings concur and differ from those of other investigators. 
Often this is done superficially with the simple goal of justifying the current results. A more 
enlightened approach, in those situations where the prior study design is indeed comparable to 
the present one, is a detailed analysis filled with sparkling insights on what the discrepancies 
suggest about the true biology of the disease, with additional analyses to investigate these 
novel possibilities.  
The same investigators or ideally an independent group should confirm the results on a 
second population of study subjects. This is essential for major findings that change routine 
practice. Cancer grading schemes are an example: a new grading scheme is not rock solid 
until it has been validated in a second population of study subjects (see Hill’s criterion of 
consistency6). We have illustrative examples of this in veterinary pathology.4,21,35,39,43,46 
Generally, we as journal editors expect that such confirmatory studies not only corroborate or 
refute the outcome of the original study, but also include additional results that add novelty to 
the new investigation. 
Finally, develop a mindset of critical analysis and skeptical interpretation of your own findings. 
Carefully probe a variety of alternative explanations. Consider the possibility of bias and how it 
might impact the findings. Don’t ignore troublesome details of the data that seem not to make 
sense. Sometimes, niggling problems are the window that opens to reveal a new landscape of 
truth. 
Conclusions 
The methods that veterinary pathologists use in observational studies are key to advancing 
knowledge of animal disease. Yet, the most-used methods in pathology are somewhat 
subjective, inherently variable, not easily quantitated, and susceptible to technical error. 
Careful attention to validation, quality control, methodologic rigor, and critical analysis of the 
results are required for advancing knowledge in veterinary pathology. 
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 Table  
Table 1. General principles for valid research methods. Many of these principles apply to 
subjective analyses such as histopathologic grading or immunohistochemistry scoring as well 
as to objective analyses such as machine-based measurements of analytes. Validation and 
quality control of the latter are beyond the scope of this article and reviewed elsewhere.9,14  
 General considerations 
o Use methodology appropriate to the objectives of the study 
o Use approaches that increase rigor, including quantitative measurements 
o Seek the advice of a statistician 
o Analyze magnitude of differences between study groups, confidence intervals of 
the estimates, and likelihood of statistical significance  
 Validate novel or newly implemented assays; ensure quality control for established 
methods 
o Use previously validated and published methods, and consult published 
guidelines for specific assays 
o Validate the method using technical and biologic controls (positive and negative) 
o Ensure that the assay measures the intended target and does not measure other 
targets (analytic specificity) 
o Determine the lower limit of detection (analytic sensitivity), and the range of valid 
measurements, when relevant 
o Where appropriate, measure diagnostic test sensitivity and specificity in a 
population of animals 
 Minimize and measure technical error (non-differential information bias) 
o Use data obtained from the primary source, not a secondary record 
o Validate information provided by others 
o Minimize variability by training and experience of personnel, validation and 
optimization of methods, standardized protocols, clear and reproducible 
methods, objective and uniformly understood criteria, and visual examples of cut-
points or diagnostic criteria 
o Assess sample quality, to avoid false negative tests 
o Positive and negative controls for the general method, and for each sample 
o Replicate unexpected or important results on a different day with different 
samples 
o Ensure one operator makes all subjective assessments, or statistically analyze 
differences between operators 
o Measure intra-observer and inter-observer variation for subjective assessments; 
measure technical variation for objective or machine-based measurements.  
 Avoid errors that differ between study groups (differential information bias) 
o Use the same methods for both groups: acquisition of case information, and 
sample collection, storage, preparation and measurement 
o Analyze the different study groups concurrently in randomized order over a short 
time period 
o Blind investigators to the identity of the study groups and to other data 
o Analyze differences between study groups in lost samples or study subjects lost 
to follow-up 
 Critically validate the study findings 
o Corroborate the results using complimentary analytic methods 
o Compare the results in many different animals 
o Carefully consider similarities and discrepancies with prior studies 
o Replicate the findings in a second population of animals 
o Critical analysis of results; consideration of alternative explanations 
  
Figure legends 
 
 
Figure 1. A visual guide is useful to clearly define a microscopic scoring scheme. This example 
illustrates key criteria for cytologic diagnosis of mild and moderate inflammatory bowel disease 
(IBD) and small cell and large cell intestinal lymphoma. The left and center columns show 
microscopic images and the right column summarizes the key criteria in a schematic. The 
criteria include a linear alignment of lymphocytes (≥5 cells per 400× field) (arrows), and nests 
of lymphocytes (≥5 clustered cells per 400× field) (arrowheads), both located at the edges of 
epithelial cell clusters. Wright Giemsa. Modified from Maeda et al,27 used with permission. 
 
  
  
Figures 2-3. Mannheimia haemolytica 
pneumonia, lung, steer. Fig 2A. Strong 
immunolabeling of leukocytes and plasma 
within the lesions. Immunohistochemistry 
using a rabbit antibody to malondialdehyde 
(a marker of lipid peroxidation). Fig 2B. 
Lack of immunolabelling in the same tissue, 
probed with normal rabbit serum. Fig 3. In a 
section of histologically normal lung from 
the same steer probed with the antibody to 
malondialdehyde, there is an absence of 
immunolabelling except for plasma within a 
blood vessel (arrow). Later analysis 
identified that the antibody was raised 
against malondialdehyde conjugated to 
bovine serum albumin, suggesting that the 
positive immunolabelling is directed against 
albumin. Western blot, not used in this 
instance, may have been useful to identify 
this cross-reaction as a cause for the false 
immunolabelling. Credit: Courtney R. 
Schott. 
 
  
 Figure 4. Human HT-1080 cells were transfected with the gene encoding canine CD3-zeta. 
Then, non-transfected (CD3 zeta-) and transfected (CD3 zeta+) cells were probed with an 
antibody to human CD3-zeta labeled with green-fluorescent protein (GFP), to validate that the 
antibody to human CD3-zeta reacted against the canine protein. The lower panels show the 
DAPI nuclear stain. 
 
  
 Figure 5. Sarcoma, skin, rabbit. A. Immunohistochemistry using a mouse monoclonal antibody 
to α-smooth muscle actin labels both the tumor and the adjacent dermis. B. With omission of 
the primary antibody, labeling of the dermis remains strong, while labeling of the tumor is 
abrogated. It was later identified that the detection system (secondary antibody) labels both 
mouse and rabbit antibodies, and the immunolabelling presumably represents rabbit 
immunoglobulin in the dermis.  
 
  
  
Figure 6. Melting peaks analysis, for quantitative PCR analysis of a fungal pathogen. The 
melting curve contains 3 peaks at approximately 78.5, 86, and 92oC, instead of the expected 
single peak. Sequence analysis (data not shown) of amplicons corresponding to the 3 peaks 
revealed a lack of primer specificity, with amplification of non-target fungal species. 
